Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27015148 | 1.00 | CXCR3 (0.89) | CXCR3CYP3A4 | |
| SCHEMBL433439 | 0.94 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL335753 | 0.94 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL29386766 | 0.94 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL12857733 | 0.94 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL27015149 | 0.89 | CXCR3 (0.87) | CXCR3CYP3A4 | |
| SCHEMBL14960668 | 0.86 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL5832823 | 0.85 | CXCR3 (0.66) | CXCR3CYP3A4 | |
| SCHEMBL29411739 | 0.84 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL22965110 | 0.84 | CXCR3 (1.00) | CXCR3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067662-B2 | CXCR3 antagonists | AMGEN SF, LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060116388-A1 | CXCR3 antagonists | TULARIK, INC. | 2006-06-01 | — | — | US | disclosed |
| US-7053215-B2 | Substituted Quinazolin-4(3H)-one compounds, compositions, and methods for their use | AMGEN SF, LLC (US) | 2006-05-30 | — | — | US | disclosed |
| US-6964967-B2 | Substituted pyrido[2,3-d]pyrimidines and methods for their use | AMGEN, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050075333-A1 | CXCR3 antagonists | TULARIK INC. | 2005-04-07 | — | — | US | disclosed |
| US-6794379-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; SKIN DISORDERS | TULARIK INC. | 2004-09-21 | — | — | US | disclosed |
| US-20030069234-A1 | CXCR3 antagonists | AMGEN INC. | 2003-04-10 | — | — | US | disclosed |
| US-20030055054-A1 | CXCR3 antagonists | TULARIK, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20020169159-A1 | An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor | TULARIK INC. (US) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075333-A1 | CXCR3 antagonists | CXCR3, CXCR1, CCR5 | CXCR3 1/4885CYP3A4 4590/4885 |
| US-20030069234-A1 | CXCR3 antagonists | CXCR3, CXCR1, CCR5 | CXCR3 1/4885CYP3A4 4590/4885 |
| US-20020169159-A1 | An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor | CCR2, CCR1, ACKR3 | CXCR3 7/4885CYP3A4 4440/4885 |
| US-20060116388-A1 | CXCR3 antagonists | CXCR3, CXCR1, CCR5 | CXCR3 1/4885CYP3A4 4590/4885 |
| US-20030055054-A1 | CXCR3 antagonists | CXCR3, CXCR1, CCR5 | CXCR3 1/4885CYP3A4 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.